JP Morgan Initiates Coverage On BridgeBio Oncology with Overweight Rating, Announces Price Target of $27
Benzinga Newsdesk 4 months ago
NewsInitiationAnalyst RatingsPrice Target
JP Morgan analyst Priyanka Grover initiates coverage on BridgeBio Oncology (NASDAQ:BBOT) with a Overweight rating and announces Price Target of $27.
JP Morgan analyst Priyanka Grover initiates coverage on BridgeBio Oncology (NASDAQ:BBOT) with a Overweight rating and announces Price Target of $27.